Метаболик синдромда ошқозон шиллиқ қаватининг морфологик жихатларидан бири, шиллиқ қаватда юза фаол гастрит кўринишидаги ўзгаришларнинг бўлиши, қопловчи эпителийларида мета-плазия, фундал безларда ўчоқли атрофик ўзгаришлар аниқланди. Жумладан, антрал сохасидаги без тузилмалари компонентларининг юза қопловчи эпителийларида сийрак толали бирикитрувчи тўқима, оралиқда интарэпи-телиал лимфоцитларни ора-сира жойлашиши, баъзиларида МАЛТ тузилма-ларининг атрофик ўзгариши, оралиқ стромада хажман кичиклашган без эпителийларини бўлиши билан характерланади
Метаболик синдромда ошқозон шиллиқ қаватининг морфологик жихатларидан бири, шиллиқ қаватда юза фаол гастрит кўринишидаги ўзгаришларнинг бўлиши, қопловчи эпителийларида мета-плазия, фундал безларда ўчоқли атрофик ўзгаришлар аниқланди. Жумладан, антрал сохасидаги без тузилмалари компонентларининг юза қопловчи эпителийларида сийрак толали бирикитрувчи тўқима, оралиқда интарэпи-телиал лимфоцитларни ора-сира жойлашиши, баъзиларида МАЛТ тузилма-ларининг атрофик ўзгариши, оралиқ стромада хажман кичиклашган без эпителийларини бўлиши билан характерланади
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Makhkamov N.J. | профессор | Андижон давлат тиббиёт институти |
| 2 | Murotov F.B. | мустакил изланувчи | Фарғона жамоат саломатлиги тиббиёт инистутити |
| № | Ҳавола номи |
|---|---|
| 1 | 1.Abell TL, Kedar A,Stocker A, Beatty K, McElmurray L, Hughes M, Rashed H, Kennedy W, Wendelschafer-Crabb G, Yang X, Fraig M, Gobejishvili L, Omer E, Miller E, Griswold M, Pinkston C. Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities.Dig Dis Sci. 2021 Apr;66(4):1127-11412.Maksud FA, Alves JS, Diniz MT, Barbosa AJ. Density of ghrelin-producing cells is higher in the gastric mucosa of morbidly obese patients. //Eur J Endocrinol. 2011 Jul;165(1):57-62.3.QuininoRME, Barbosa ALC, de Araújo Barros Xavier M, de Lima França R, de Freitas MPC, Goldenberg A. Analysis of the Immunohistochemical Expression of Ghrelin in the Gastric Mucosa and Correlation with Weight Loss After Sleeve Gastrectomy. Obes Surg. 2022 Nov;32(11):3687-3695.4.Mehdar KM, Alsareii SA, Alshafie SEM, Al-Rafiah AR, Alamri AM. Ghrelin gastric tissue expression in patients with morbid obesity and type 2 diabetes submitted to laparoscopic sleeve gastrectomy: immunohistochemical and biochemical study. Folia Histochem Cytobiol. 2020;58(4):235-246.5.Gündoğan M, Çalli Demırkan N, Tekın K, Aybek H. Gastric histopathological findings and ghrelin expression in morbid obesity. TurkPatoloji Derg. 2013;29(1):19-26.6.Musella M, Di Capua F, D'Armiento M, Velotti N, Bocchetti A, Di Lauro K, Galloro G, Campione S, Petrella G, D'Armiento FP. No Difference in Ghrelin-Producing Cell Expression in Obese Versus Non-obese Stomach: a ProspectiveHistopathological Case-Control Study. Obes Surg. 2018 Nov;28(11):3604-36107.Parada DD, Peña G KB, Vives M, Molina A, Mayayo E, Riu F, Sabench F, Del Castillo D. Quantitative and Topographic Analysis by Immunohistochemical Expression of Ghrelin Gastric Cells in Patients with Morbid Obesity. Diabetes Metab Syndr Obes. 2020 Aug 18;13:2855-2864.8.Wei Z, Liang L, Junsong L, Rui C, Shuai C, Guanglin Q, Shicai H, Zexing W, Jin W, Xiangming C, Shufeng W. The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. J Exp Clin Cancer Res. 2015 Jun 18;34(1):64.9.Renehan AG, Margaret T, Matthias E, Heller RF, Marcel Z. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578. 10.Wolin KY, Carson K, ColditzGA. Obesity and cancer. Oncologist. 2013;15:556–565. doi: 10.1634/theoncologist.2009-0285. 11.Roberts DL, Dive C, Renehan AG. Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives. Annu. Rev. Med. 2010;61:301–16. 12.Lashinger LM, Rossi EL,Hursting SD. Obesity and Resistance to Cancer Chemotherapy: Interacting Roles of Inflammation and Metabolic Dysregulation. Clin. Pharmacol. Ther. 2014;96:458–6313.Zou Y, Wu L, Yang Y, Ding Z, Huang J, Li P, Zhu C, Yuan Y. Serum lipid levels correlate to theprogression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study. Transl Oncol. 2021 Jan;14(1):100925.14.Zou Y, Yu X, Zhou C, Zhu C, Yuan Y. Adverse effects of low serum lipoprotein cholesterol on the immune microenvironment in gastric cancer: a case‒control study. Lipids Health Dis. 2022 Dec 31;21(1):150.15.Pih GY, Gong EJ, Choi JY, Kim MJ, Ahn JY, Choe J, Bae SE, Chang HS, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH, Jung HY. Associations of Serum Lipid Levelwith Gastric Cancer Risk, Pathology, and Prognosis. Cancer Res Treat. 2021 Apr;53(2):445-456.16.Zou Y, Li D, Yu X, Zhou C, Zhu C, Yuan Y. Correlation of Neuroendocrine Differentiation with a Distinctively Suppressive Immune Microenvironment in Gastric Cancer. Neuroendocrinology. 2024;114(2):192-206.17.Board WCoTE . Digestive system tumours: WHO classification of tumours. 5th ed. World Health Organization; 2019. |